MEDICAL PROGNOSIS INSTITUTE A/S

Inactive Instrument

Insiders Medical Prognosis Institute A/S Nasdaq Copenhagen

Equities

MPIT

DK0060732477

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Allarity Therapeutics, Inc. Announces Termination of Marie Foegh as Chief Medical Officer	Mar. 04	CI
Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board	Feb. 01	CI
Allarity Therapeutics Announces Executive Changes	Dec. 12	CI
Allarity Therapeutics, Inc. Announces Chief Executive Officer Changes	Dec. 11	CI
Allarity Therapeutics, Inc. Announces Board Changes	23-08-11	CI
Allarity Therapeutics, Inc. Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives	23-07-24	CI
Allarity Therapeutics, Inc. Announces Board Changes	23-01-20	CI
Allarity Therapeutics, Inc. Announces the Appointment of Jerry Mclaughlin as a Member of its Board of Directors, Effective October 1, 2022	22-09-26	CI
Allarity Therapeutics : Shareholder Director Nomination - Form 8-K	22-08-16	PU
Allarity Therapeutics Announces Appointment of New Members to Its Board of Directors	22-07-11	CI
Allarity Therapeutics Names James Cullem as Interim CEO, Joan Brown as Interim CFO	22-06-29	MT
Allarity Therapeutics, Inc. Announces CEO Changes	22-06-29	CI
Allarity Therapeutics, Inc. Announces Executive Leadership Transition	22-06-29	CI
Allarity Therapeutics, Inc. Appoints Roberto Pili as Member of the Company’s Scientific Advisory Board	22-06-15	CI
Oncology Venture A/S Announces Management Changes	19-09-04	CI
Oncology Venture A/S Announces Board Changes; Amends the Articles of Association	18-12-18	CI
Oncology Venture Sweden AB Announces Executive Changes	18-02-05	CI
Oncology Venture Sweden AB Announces Executive Changes	17-04-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer